Global Age-Related Macular Degeneration Market Forecast Report by Disease Type Product Distribution Channel Countries and Company Analysis, 2024-2032

Age-Related Macular Degeneration Market Analysis

The Global Age-Related Macular Degeneration market is forecasted to reach US$ 19.53 billion by 2032 from US$ 10.68 billion in 2023, and compound annual growth rate of 6.94% from 2024 to 2032. Market growth is for the aging population vulnerable to macula cell damage due to the changes in structure and blood flow. More cases of the risks such as genetic predisposition, high blood pressure, smoking, long exposure to close working on blue light devices, bad diet and obesity are on the rise implying that the markets for these diseases are likely to expand.

Age-Related Macular Degeneration Market Outlook

AMD or the Age-related macular degeneration is a degenerative disease that targets a tiny pocket in the retina known as the macula. This part is vital in activities that require high level of focus such as reading and driving since it offers the central vision. AMD is a common cause of blindness in the elderly specifically the people who are aged 50 years and above. There are two main types: dry AMD that is caused by the degeneration of light-sensitive cells in the macular and wet AMD, which is caused by the growth of abnormal blood vessels that leak into the retina.

Management and control of the physical manifestations and the diseases' progression are the goals of treatment. For dry AMD, treatments include vitamins like vitamin C, vitamin E, zinc, copper, and antioxidants which can in instances slow down vision loss. wAMD is typically treated with intravitreal injections of anti-vascular endothelial growth factor agents since they prevent the formation of abnormal blood vessels, thus maintaining vision. Further investigations are conducted to find additional treatment for the disease, a different approach towards the diagnosis of the condition, and adjustment to the ways, in which it affects the life of an AME patient.

Growth Factors of the Age-Related Macular Degeneration Market

Aging Population Dynamics

Increasing incidence of AMD is primarily attributed to the growing aging population pool especially in the developed regions such as Europe and North America. Age is another risk factor for AMD; this eye condition is more common in persons older than 50 years of age. This demographic trend escalates the need to deliver diagnostic tools, treatments, and support care to optimally treat and manage vision loss due to AMD. As per the current patients' demographic trends, it is noticed that the healthcare systems are changing for addressing the requirements of such patients contributing to a market growth with enhanced diagnosis ratios and treatment strategies.

Advancements in Treatment Options

Frequent and notable improvements in the management of patients with AMD have led to changes in the patient's prognosis. Currently, the invention of Anti-VEGF agents in the likes of ranibizumab and aflibercept has enhanced wet AMD administration via controlling growth of new blood vessels. Such therapies assist with the stabilization of vision and even vision improvement in some cases while ultimately boosting the patients' quality of life. New drug delivery forms as well as the combo therapies also promote research to continue to fuel the market.

Technological Innovations in Diagnostic Tools

New technologies in ocular imaging including, OCT and FAF facilitate early diagnosis of AMD. It is important since it can be detected early enough and hence early treatment and control hence a better outcome for the patients. The integration of these hi-tech imaging techniques into the healthcare systems accurately diagnose clients and further facilitate the delivery of individualized care, thus driving the market.

Increasing Awareness and Healthcare Infrastructure

Raising public awareness about potential symptoms, causes, and current treatment options of the AMD is vital to initiate preventive measures. Moreover, related investing in healthcare infrastructure, especially in the areas where the demographic shift affects the augmentation in the AMD affected population, enhances AMD access. Improvement of healthcare leads to timely health check-ups, better health awareness, appropriate patient management, and lower incidences of vision loss thus contributes to the growth of the market.

Europe Age-Related Macular Degeneration Market

The European age-related Macular Degeneration (AMD) Market to experience steady growth due to the following factors. Since elder people are more probable to be affected by AMD, the market is more developed in countries like Germany, the UK, and Italy. Development in healthcare facilities along with growing awareness level of patients in case of eye diseases provide additional support to the market need of diagnostics and therapies. Medical advancements, especially in a new therapy that targets wet AMD, are major influencers, as they provide ways to easily treat and save a patient's eyesight. This is fostered by government policies that encourage development of researches focused on appropriate treatments for ophthalmic ailments. Given the rising incidence of AMD owing to population ageing and other factors, the market for treating AMD is expected to grow in Europe; this therefore provides opportunities for biopharmaceutical firms to fulfill the needs of patients in this market.

Age-Related Macular Degeneration Company Overview

F. Hoffmann-La Roche Ltd., Bayer AG, Abbvie, GSK Plc, Novartis AG, Regeneron Pharmaceuticals, Bausch Health Companies Inc., and Alimera Sciences Inc. are among the industry leaders in the Global Age-Related Macular Degeneration Market.

Age-Related Macular Degeneration News

In March 2024, Sumitomo Corporation and Roche Pharma India signed a commercial alliance agreement for Vabysmo (faricimab), a new medicine used to treat diabetic macular edema (DME) and neovascular or "wet" age-related macular degeneration (nAMD). This marks Roche Pharma India's first entry into the ophthalmology market. Vabysmo is claimed to be a dual pathway inhibitor, targeting two disease processes associated with retinal disorders that can impair vision.

In August 2024, Astellas' IZERVAYTM was approved by the FDA to treat geographic atrophy (G.A.) secondary to AMD. In Phase III studies, IZERVAY demonstrated a statistically significant reduction in the rate of G.A. progression compared to other approved therapies.

Mode of Transportation - Market breakup in 4 viewpoints:

1. Refrigerated Road Transport

2. Refrigerated Sea Transport

3. Refrigerated Rail Transport

4. Refrigerated Air Transport

Technology - Market breakup in 4 viewpoints:

1. Vapor Compression Systems

2. Air-Blown Evaporators

3. Eutectic Devices

4. Cryogenic Systems

Temperature - Market breakup in 2 viewpoints:

1. Single Temperature

2. Multi-Temperature

Application - Market breakup in 3 viewpoints:

1. Chilled Food Products

2. Frozen Food Products

3. Others

Country - Market breakup in 25 viewpoints:

North America

United States

Canada

Europe

France

Germany

Italy

Spain

United Kingdom

Belgium

the Netherlands

Turkey

Asia Pacific

China

Japan

India

Australia

South Korea

Thailand

Malaysia

Indonesia

New Zealand

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

United Arab Emirates

All the Key players have been covered from 4 Viewpoints:

1. Overview

2. Recent Development & Strategies

3. Product Portfolio

4. Financial Insights

Company Analysis:

1. F. Hoffmann - La Roche Ltd.

2. Bayer AG

3. Abbvie

4. GSK Plc

5. Novartis AG

6. Regeneron Pharmaceuticals

7. Bausch Health Companies Inc.

8. Alimera Sciences Inc.